A 58-year-old man with Parkinson disease has been on levodopa for 3 years and now presents with involuntary choreiform movements of the limbs that occur when drug levels are at their peak. Which feature best distinguishes this adverse effect from the motor complications seen with dopamine agonist monotherapy?

Explanation

## Dyskinesias: Levodopa vs Dopamine Agonists ### Clinical Presentation Distinction **Key Point:** Peak-dose dyskinesias (levodopa-induced) are **temporally synchronized with plasma drug concentration peaks**, whereas dopamine agonist-induced dyskinesias are **dose-independent** and occur as a consequence of chronic dopaminergic stimulation and striatal sensitization, not acute drug levels. ### Temporal and Pharmacokinetic Relationship | Feature | Levodopa Peak-Dose Dyskinesias | Dopamine Agonist Dyskinesias | |---------|--------------------------------|------------------------------| | **Timing** | Coincides with peak plasma levels (30–60 min post-dose) | Occurs throughout the day; independent of dose timing | | **Mechanism** | Pulsatile dopamine release → striatal sensitization | Chronic tonic dopaminergic stimulation + receptor supersensitivity | | **Relationship to dose** | Directly proportional; worse at higher doses | Develops regardless of dose magnitude | | **Predictability** | Highly predictable; occurs at same time each day | Unpredictable; may fluctuate with disease progression | | **Response to dose reduction** | Often improves with dose reduction | Minimal improvement; may require drug discontinuation | ### Pathophysiology **Levodopa-induced peak-dose dyskinesias:** 1. Short half-life (~60–90 min) causes pulsatile striatal dopamine surges 2. Denervated striatum loses ability to buffer dopamine fluctuations 3. Pulsatile stimulation → abnormal synaptic plasticity and receptor sensitization 4. Dyskinesias appear when dopamine levels spike 5. Dyskinesias resolve when levels fall (off-phase) **Dopamine agonist dyskinesias:** 1. Continuous, tonic receptor stimulation over months to years 2. Chronic activation → striatal sensitization and maladaptive plasticity 3. Dyskinesias emerge as a consequence of cumulative dopaminergic exposure 4. Not acutely linked to plasma drug concentration 5. Persist throughout the day, independent of dosing schedule **High-Yield:** The **temporal coupling to peak plasma levels** is the cardinal distinguishing feature of levodopa dyskinesias. This is why extended-release levodopa formulations and addition of COMT inhibitors (to smooth dopamine delivery) can reduce peak-dose dyskinesias. **Clinical Pearl:** A patient with peak-dose dyskinesias on levodopa can be managed by: - Reducing individual dose (but increasing frequency) - Switching to extended-release formulations - Adding COMT inhibitors (entacapone, tolcapone) to prolong levodopa half-life - Adding dopamine agonists to provide continuous dopaminergic tone ### Why Other Options Are Incorrect Option 1 (dose reduction response) is partially true—peak-dose dyskinesias *may* improve with dose reduction—but this is not a reliable discriminator, as agonist dyskinesias can also sometimes improve with dose adjustment. Option 2 (anatomical distribution) is not a valid discriminator; both levodopa and agonist dyskinesias can affect any body region depending on individual striatal pathology. Option 3 (reversibility) is misleading. While peak-dose dyskinesias may resolve if levodopa is withdrawn, this is not clinically practical; moreover, agonist dyskinesias can also partially resolve with discontinuation. The key distinction is the temporal pattern, not reversibility.